| 1 |
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
Andrew Blauvelt, Richard G B Langley, J.‐P. Lacour et al. · Journal of the American Academy of Dermatology
Open access |
18 Jul 2022 |
79 |
| 2 |
Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL ‐13 inhibition
Eric Lawrence Simpson, Emma Guttman‐Yassky, Lawrence F. Eichenfield et al. · Allergy
Open access |
16 Jul 2023 |
41 |
| 3 |
Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis
Joseph Frank Merola, Daniel C. Butler, Thomas Mark et al. · JAMA Dermatology
Open access |
23 Aug 2023 |
23 |
| 4 |
Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)
Eric Lawrence Simpson, Andreas Wollenberg, Weily Soong et al. · Annals of Allergy Asthma & Immunology
Open access |
14 Jul 2022 |
18 |
| 5 |
Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States
Jashin J. Wu, Karen A. Veverka, Minyi Lu et al. · Journal of Dermatological Treatment
|
11 Oct 2018 |
18 |
| 6 |
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis
Linda Stein Gold, Jes Birger Hansen, Dharm S. Patel et al. · Journal of the American Academy of Dermatology
Open access |
16 May 2020 |
16 |
| 7 |
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment
Joe Gorelick, Andrea Nguyen, Shannon Schneider et al. · American Journal of Clinical Dermatology
Open access |
16 Jan 2025 |
14 |
| 8 |
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE)
Sascha Gerdes, Manuel Velasco, Jashin J. Wu et al. · Journal of Dermatological Treatment
|
28 Jan 2020 |
14 |
| 9 |
The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment
Jashin J. Wu, Minyi Lu, Karen A. Veverka et al. · Journal of Dermatological Treatment
Open access |
17 Dec 2018 |
14 |
| 10 |
Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment
Steven R. Feldman, Annie Guérin, Marjolaine Gauthier‐Loiselle et al. · Journal of Dermatological Treatment
Open access |
5 May 2024 |
12 |
| 11 |
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1
Eric Lawrence Simpson, Andrew Blauvelt, Jonathan I. Silverberg et al. · American Journal of Clinical Dermatology
Open access |
7 Oct 2023 |
11 |
| 12 |
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
Andrew Blauvelt, Melinda Gooderham, Neal D Bhatia et al. · Dermatology and Therapy
Open access |
24 Sep 2022 |
9 |
| 13 |
Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis
Jashin J. Wu, Jes Birger Hansen, Dharm S. Patel et al. · Journal of Medical Economics
Open access |
27 Jan 2020 |
9 |
| 14 |
Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study.
Dharm S. Patel, Karen A. Veverka, Jes Birger Hansen et al. · PubMed
Open access |
May 2020 |
8 |
| 15 |
Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs
Carl Victor Asche, Min‐Chul Kim, Steven R. Feldman et al. · Journal of Medical Economics
Open access |
5 Jun 2017 |
8 |
| 16 |
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry
Dawn Zhang Eichenfield, Keith D. Knapp, Ami J. Claxton et al. · Dermatitis
|
19 Feb 2025 |
7 |
| 17 |
Burden, Control, and Treatment of Moderate to Severe Atopic Dermatitis in 2021: A United States Patient Survey Study
Peter Lio, deMauri S. Mackie, Dawn Bates et al. · Journal of Drugs in Dermatology
Open access |
2023 |
5 |
| 18 |
An assessment of the relationship between pharmacy students’ perceptions of their preparedness to contribute to emergency responses and their current work status
Salome Bwayo Weaver, La’Marcus T. Wingate, Nikeshia Dunkelly-Allen et al. · Currents in Pharmacy Teaching and Learning
|
15 Sep 2018 |
4 |
| 19 |
The Impact of Chronic Hand Eczema on Occupation, Work Productivity, and Activity Impairment – Results From the CHECK Study in the United States
Eric Lawrence Simpson, Sanjeev Balu, Aseel Bin Sawad et al. · SKIN The Journal of Cutaneous Medicine
Open access |
10 Nov 2025 |
3 |
| 20 |
Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16
Amy S. Paller, Andrew Blauvelt, Weily Soong et al. · Dermatology and Therapy
Open access |
28 Jul 2025 |
3 |
| 21 |
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry
Michael A. Haft, Keith D. Knapp, Ami J. Claxton et al. · Current Medical Research and Opinion
|
Dec 2024 |
3 |
| 22 |
Self-Reported Disease Severity, Symptoms, and Treatment of Chronic Hand Eczema – Results From the CHECK Study in the United States
Raj Chovatiya, Sanjeev Balu, Aseel Bin Sawad et al. · SKIN The Journal of Cutaneous Medicine
Open access |
10 Nov 2025 |
2 |
| 23 |
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials
Tiffany T. Mayo, Jonathan I. Silverberg, April Wang Armstrong et al. · American Journal of Clinical Dermatology
Open access |
21 Oct 2025 |
2 |
| 24 |
Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities
Amy S. Paller, Weily Soong, Mark Boguniewicz et al. · Annals of Allergy Asthma & Immunology
Open access |
22 Jun 2025 |
2 |
| 25 |
557 - Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE study in the United States
April Wang Armstrong, Cory Rubin, Abel D. Jarell et al. · British Journal of Dermatology
|
Feb 2024 |
2 |
| 26 |
544 - Cost-per-responder analysis of tralokinumab versus dupilumab in patients with moderate-to-severe atopic dermatitis in the US and Canada
Jashin J. Wu, Sanjeev Balu, Nikolaj Birk Larsen et al. · British Journal of Dermatology
|
Feb 2024 |
2 |
| 27 |
43946 Neutralization of IL-13 by tralokinumab improves atopic dermatitis endotypes characterized by S. aureus colonization
Eric Lawrence Simpson, Mark Boguniewicz, Lawrence F. Eichenfield et al. · Journal of the American Academy of Dermatology
Open access |
Sep 2023 |
2 |
| 28 |
Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis
SCOTT R. FREEMAN, Miriam S. Bettencourt, Meg Corliss et al. · SKIN The Journal of Cutaneous Medicine
Open access |
2 Sep 2020 |
2 |
| 29 |
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial
Melinda Gooderham, Christopher G. Bunick, JiaDe Yu et al. · Dermatology and Therapy
Open access |
17 May 2026 |
1 |
| 30 |
The Multifactorial and Heterogenous Nature of Chronic Hand Eczema Seen in Clinical Practice in the United States Results from the RWEAL-US Study
Raj Chovatiya, Sanjeev Balu, Aseel Bin Sawad et al. · SKIN The Journal of Cutaneous Medicine
Open access |
11 May 2026 |
1 |
| 31 |
Treatment Patterns in Chronic Hand Eczema in the US Results from the RWEAL-US Medical Chart Review
Raj Chovatiya, Sanjeev Balu, Aseel Bin Sawad et al. · SKIN The Journal of Cutaneous Medicine
Open access |
11 May 2026 |
1 |
| 32 |
Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis
April W. Armstrong, Rebecca M. Burne, Aseel Bin Sawad et al. · Dermatology and Therapy
Open access |
24 Apr 2026 |
1 |
| 33 |
Demographics, Clinical, and Treatment Characteristics of Patients With Moderate to Severe Chronic Hand Eczema in the United States – A Retrospective Claims Analysis
April W. Armstrong, Rebecca M. Burne, Aseel Bin Sawad et al. · SKIN The Journal of Cutaneous Medicine
Open access |
10 Nov 2025 |
1 |
| 34 |
Demographics and Clinical Characteristics of Chronic Hand Eczema patients – Results from the CHECK study in the United States
Eric Lawrence Simpson, Sanjeev Balu, Aseel Bin Sawad et al. · SKIN The Journal of Cutaneous Medicine
Open access |
10 Nov 2025 |
1 |
| 35 |
553 - Tralokinumab real-world patient-reported outcomes in moderate-to-severe atopic dermatitis adult patients in the United States: 6-month interim analysis
Peter Lio, Yestle Kim, Sanjeev Balu et al. · British Journal of Dermatology
|
Feb 2024 |
1 |
| 36 |
548 - Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities
Amy S. Paller, Weily Soong, Mark Boguniewicz et al. · British Journal of Dermatology
|
Feb 2024 |
1 |
| 37 |
549 - Laboratory parameters in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial
Amy S. Paller, Michael J. Cork, Chih-ho Hong et al. · British Journal of Dermatology
|
Feb 2024 |
1 |
| 38 |
546 - Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment
Steven R. Feldman, Annie Guérin, Marjolaine Gauthier‐Loiselle et al. · British Journal of Dermatology
|
Feb 2024 |
1 |
| 39 |
Tralokinumab Real-World Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis Adult Patients in the United States: 6-Month Interim Analysis
Peter Lio, Yestle Kim, Sanjeev Balu et al. · SKIN The Journal of Cutaneous Medicine
Open access |
16 Jan 2024 |
1 |
| 40 |
Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 years and Older With and Without Atopic Comorbidities
Amy S. Paller, Weily Soong, Mark Boguniewicz et al. · SKIN The Journal of Cutaneous Medicine
Open access |
16 Jan 2024 |
1 |
| 41 |
405 Understanding patient experience and factors influencing patient preference in the treatment of moderate-to-severe atopic dermatitis through in-depth qualitative patient interviews
Steven R. Feldman, Annie Guérin, Marjolaine Gauthier‐Loiselle et al. · British Journal of Dermatology
|
Jun 2023 |
1 |
| 42 |
Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment
April W. Armstrong, Aseel Bin Sawad, Nisha C. Hazra et al. · Dermatology and Therapy
Open access |
12 Jun 2026 |
0 |
| 43 |
Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis
Reece Grindley, Linnea Houde, Aseel Bin Sawad et al. · Journal of Comparative Effectiveness Research
Open access |
9 Jun 2026 |
0 |
| 44 |
Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial
Amy S. Paller, Michael J. Cork, H. Chih-ho Hong et al. · Dermatology and Therapy
Open access |
25 Apr 2026 |
0 |
| 45 |
Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure
Holm Schneider, Christopher G. Bunick, Kathrin Hillmann et al. · British Journal of Clinical Pharmacology
Open access |
17 Dec 2025 |
0 |
| 46 |
Exposition systémique négligeable au delgocitinib chez les patients utilisant le delgocitinib en crème à dose maximale pour le traitement d’un eczéma chronique des mains
Delphine Staumont-Sallé, Melinda Gooderham, Lawrence F. Eichenfield et al. · Annales de Dermatologie et de Vénéréologie - FMC
|
13 Nov 2025 |
0 |
| 47 |
« Super-réponse » après traitement par delgocitinib 20 mg/g en crème dans un sous-groupe de patients atteints d’eczéma chronique des mains modéré à sévère
C. Bernier, April W. Armstrong, Robert Bissonnette et al. · Annales de Dermatologie et de Vénéréologie - FMC
|
13 Nov 2025 |
0 |
| 48 |
Healthcare Resource Utilization and Financial Burden Among Patients With Chronic Hand Eczema – Results From the CHECK Study in the United States
Raj Chovatiya, Sanjeev Balu, Aseel Bin Sawad et al. · SKIN The Journal of Cutaneous Medicine
Open access |
10 Nov 2025 |
0 |
| 49 |
Estimated Conjunctivitis-Related Healthcare Cost Savings With Increased Tralokinumab Use Versus Other Biologics Among Patients With Moderate-Severe Atopic Dermatitis in the United States
Sanjeev Balu, Jessica Maitland, Marjolaine Gauthier‐Loiselle et al. · SKIN The Journal of Cutaneous Medicine
Open access |
10 Nov 2025 |
0 |
| 50 |
Budget Impact Analysis of Delgocitinib Cream for Moderate to Severe Chronic Hand Eczema in the United States
Jianni Singh-Landa, Aseel Bin Sawad, Yasmin Bappoo et al. · SKIN The Journal of Cutaneous Medicine
Open access |
10 Nov 2025 |
0 |